As of today (2022-08-13), Illumina's share price is $208.325.
Illumina's Owner Earnings per Share (TTM) ended in Mar. 2022 was $3.13. It's Price-to-Owner-Earnings for today is 66.56.
The historical rank and industry rank for Illumina's Price-to-Owner-Earnings or its related term are showing as below:
ILMN'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.62 Med: 61.15 Max: 116.41
Current: 66.64
During the past 13 years, the highest Price-to-Owner-Earnings of Illumina was 116.41. The lowest was 20.62. And the median was 61.15.
ILMN's Price-to-Owner-Earnings is ranked worse than 86.05% of 86
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.11
vs ILMN: 66.64
As of today (2022-08-13), Illumina's share price is $208.325.
Illumina's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $4.60. Therefore, Illumina's PE Ratio for today is 45.29.
As of today (2022-08-13), Illumina's share price is $208.325.
Illumina's EPS without NRI for the trailing twelve months (TTM) ended in was $4.60. Therefore, Illumina's PE Ratio without NRI for today is 45.29.
During the past 13 years, Illumina's highestPE Ratio without NRI was 202.38. The lowest was 32.02. And the median was 64.45.
Illumina Price-to-Owner-Earnings Historical Data
The historical data trend for Illumina's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Illumina Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Price-to-Owner-Earnings
32.70
59.79
62.35
67.83
103.38
Illumina Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Price-to-Owner-Earnings
66.77
91.35
75.10
103.38
111.77
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Price-to-Owner-Earnings Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Illumina's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Illumina's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Illumina's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
19.12(8.4%) Volume: 6,549,789 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
